SCHEDULE 13G/A: Harris Associates Discloses 4.1% Stake in Centene Corp

Harris Associates L.P. and its general partner reported a beneficial ownership of 4.1% in Centene Corp's common stock as of June 30, 2025.

Summary

• Harris Associates L.P. and Harris Associates, Inc. (its General Partner) filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in Centene Corp.
• As of June 30, 2025, the reporting persons beneficially owned an aggregate of 20,418,731 shares of Centene Corp's Common Stock.
• This aggregate amount represents 4.1% of Centene Corp's outstanding common stock.
• Harris Associates L.P. holds sole voting power over 18,043,616 shares and sole dispositive power over 20,418,731 shares.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Centene Corp.

Sentiment

Score: 6

Explanation: The filing indicates a significant institutional investor, Harris Associates, maintains a substantial stake in Centene Corp, which is generally a positive signal of investor confidence. However, as an amendment reporting a 4.1% stake (below the 5% initial filing threshold), it could imply a reduction from a previously higher holding, which would be a slight negative.

Positives

• A significant institutional investor, Harris Associates, maintains a substantial stake in Centene Corp, indicating continued confidence in the company's long-term prospects.
• The filing explicitly states the holding is for ordinary course of business, not for control, which suggests a passive, long-term investment strategy.

Negatives

• The reported ownership of 4.1% is below the 5% threshold, which, as an amendment, suggests a reduction from a previously higher stake held by Harris Associates. A decrease in a significant institutional holding could be perceived negatively by the market.

Risks

• The filing itself does not detail specific risks related to Centene Corp's operations or financial health; it is a disclosure of beneficial ownership.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding Centene Corp's future performance or Harris Associates' investment strategy beyond the certification that the shares are held in the ordinary course of business.

Industry Context

Large institutional holdings like that of Harris Associates in Centene Corp are common in the healthcare sector, reflecting the long-term investment potential and stability often associated with established healthcare providers. Such filings provide transparency into significant investor positions, which can influence market perception and investor confidence in the company.

Comparison to Industry Standards

• The 4.1% stake is significant but falls below the 5% threshold typically associated with new major institutional disclosures.
• Compared to passive index funds like Vanguard or BlackRock, which often hold 8-12% stakes in large healthcare companies such as UnitedHealth Group or CVS Health, Harris Associates' position is more indicative of an active, conviction-based investment rather than broad market tracking.
• This level of ownership suggests a substantial, but not controlling, interest, aligning with the stated purpose of holding shares in the ordinary course of business.

Stakeholder Impact

• Shareholders: Provides transparency on a significant institutional holding, potentially influencing investor sentiment.
• Company Management: Awareness of a major investor's position, though Harris Associates certifies it's not for control.

Key Dates

Recommendation

This Schedule 13G filing primarily serves as a disclosure of Harris Associates' beneficial ownership in Centene Corp. While the 4.1% stake is substantial and indicates continued institutional interest, the filing itself does not provide new fundamental information about Centene's operational performance, strategic direction, or financial health that would warrant a change in investment thesis. As an amendment, and with the stake below 5%, it's a routine update. Therefore, a 'hold' recommendation is appropriate, maintaining existing positions based on prior analysis of Centene's fundamentals, as this filing does not present a compelling reason to buy or sell.

Keywords

Centene Corp, Harris Associates, Institutional Ownership, SEC Filing, Schedule 13G, Common Stock, Healthcare, Investment Adviser, Beneficial Ownership